A comparison of 120 W laser photoselective vaporization versus transurethral resection of the prostate for bladder outlet obstruction by prostate cancer

View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2015Author
Altay, BülentErkurt, Bülent
Kiremit, Murat Can
Horuz, Rahim
Güzelburç, Vahit
Albayrak, Selami
Metadata
Show full item recordCitation
Altay, B., Erkurt, B., Kiremit, M. C., Horuz, R., Güzelburç, V. ve Albayrak, S. (2015). A comparison of 120 W laser photoselective vaporization versus transurethral resection of the prostate for bladder outlet obstruction by prostate cancer. Urologia Internationalis, 94(3), 326-329. https://dx.doi.org/10.1159/000366209Abstract
Objective: To compare the mid-term outcomes of photoselective vaporization of prostate (PVP) with GreenLight HPS 120 W laser and transurethral resection of the prostate (TURP) for obstructive lower urinary tract symptoms (LUTS) in men with prostate cancer (CaP). Patients and Methods: Seventy four patients with locally advanced (T3/T4) CaP with severe LUTS or acute urinary retention (AUR) were allocated to TURP (n = 36) or PVP (n = 38). International Prostate Symptom Scores (IPSS), maximum flow rates (Qmax) and post-void residual volumes (V-res), PSA levels, prostate volumes, complications, catheter removal and hospitalization periods were recorded. Patients were reassessed at 3, 6, and 12 months. Results: The catheter removal time was significantly longer in the TURP group (3.8 +/- 1.1 vs. 1.2 +/- 0.7 days, p = 0.02), whereas failure of initial voiding trial was higher in PVP (2.7 vs. 13.1%, p = 0.01). No significant difference in IPSS, Qmax and V-res values was observed within the follow-up period between two groups. A significant difference in urethral stricture rate (8.3 vs. 0%), catheter removal time (3.8 +/- 11 vs. 1.2 +/- 0.7 days) and hospital stay ( 2.9 +/- 0.6 vs. 1.1 +/- 0.5 days) was observed in favor of PVP. Conclusions: Palliative PVP is very safe and effective by means of symptomatic relief in patients with locally advanced CaP.
WoS Q Kategorisi
Q3xmlui.dri2xhtml.METS-1.0.item-scopusquality
Q2Source
Urologia InternationalisVolume
94Issue
3Collections
- Makale Koleksiyonu [3266]
- PubMed İndeksli Yayınlar Koleksiyonu [3575]
- Scopus İndeksli Yayınlar Koleksiyonu [5488]
- WoS İndeksli Yayınlar Koleksiyonu [5676]
Related items
Showing items related by title, author, creator and subject.
-
Re: Fascelli et al: Combined biparametric prostate magnetic resonance ımaging and prostate-specific antigen in the detection of prostate cancer: A validation study in a biopsy-naive patient population (urology 2016; 88:125-134)
Sertkaya, Zülfü (Elsevier Science Inc, 2016)I read with interest the article by Fascelli et al1The authorsaimed to validate the use of biparametric (T2- and diffusion-weighted) magnetic resonance imaging and prostate-specific antigen (PSA) or PSA density in a ... -
Acute prostatitis after prostate biopsy under ciprofloxacin prophylaxis with or without ornidazole and pre-biopsy enema: analysis of 3.479 prostate biopsy cases
Balaban, Muhsin; Özkaptan, Orkunt; Sevinç, Cüneyd; Boz, Mustafa Yücel; Horuz, Rahim; Kafkaslı, Alper; Cangücen, Önder (Brazilian Society of Urology, 2020)Objectives: To investigate the characteristics of cases of NIH category I acute prostatitis developed after transrectal prostate biopsy and clarifiy the risk factors and preventive factors. Materials and Methods: We ... -
Role of multiparametric prostate MRI in the management of prostate cancer
O'Connor, Luke P.; Lebastchi, Amir H.; Horuz, Rahim; Rastinehad, Ardeshir R.; Siddiqui, M. Minhaj; Grummet, Jeremy; Kastner, Christof; Ahmed, Hashim U.; Pinto, Peter A.; Türkbey, Barış (Springer, 2021)Introduction Prostate cancer has traditionally been diagnosed by an elevation in PSA or abnormal exam leading to a systematic transrectal ultrasound (TRUS)-guided biopsy. This diagnostic pathway underdiagnoses clinically ...